Related Experiment Video

Updated: Jul 16, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

407

Checkpoint inhibitor antibody type influences the development of cutaneous immune-related adverse events: A

Katie Roster1, Ahmad Rajeh1, Nga Nguyen1

  • 1Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts.

Journal of the American Academy of Dermatology
|September 20, 2023
PubMed
Abstract

No abstract available in PubMed .

Keywords:
antibodycutaneous adverse eventsimmune checkpoint inhibitor combination therapyimmunogenicity

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.2K
Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

3.6K

Related Experiment Videos

Last Updated: Jul 16, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

407
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.2K
Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

3.6K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Allergic Drug Reactions01:27

Allergic Drug Reactions

875
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
875

Articles linked to this work by shared authors, journal, and citation graph.

Risk factors for the development of acral melanoma: A multi-institutional, retrospective cohort study.

JAAD international·2026

Magnetic resonance imaging findings of degenerating uterine fibroids: A pictorial review.

Journal of clinical imaging science·2026

Why condition cash transfers? A multimethod pilot study evaluating the conditioning of cash transfers for tuberculosis treatment.

BMC health services research·2026

Histopathology-centered computational evolution of spatial omics: integration, mapping, and foundation models.

Briefings in bioinformatics·2026

Retargeted serine integrases for one-step, precise integration of large DNA sequences in human cells.

Nature biotechnology·2026

The Evolving Clinical Utility of Gene Expression Profiling in Cutaneous Melanoma.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Real-World Systemic Treatment Outcomes for Moderate-to-Severe Atopic Dermatitis in Children by Skin Color: 4-Year Results from the observational, international, real-world PEDISTAD Registry.

Journal of the American Academy of Dermatology·2026

Antibiotic Prophylaxis for Dermatologic Surgery. Part 1: Indications, Guidelines, and Special Populations.

Journal of the American Academy of Dermatology·2026

Dermatological Manifestations of Emergent Viruses. Part II: Vector-Borne and Opportunistic Viral Infections.

Journal of the American Academy of Dermatology·2026

Dermatological Manifestations of Emergent Viruses. Part I: Common and Vaccine-Preventable Viral Infections.

Journal of the American Academy of Dermatology·2026

Antibiotic Prophylaxis for Dermatologic Surgery. Part II: Practicing Antibiotic Stewardship - Risks, Resistance, and Responsible Use.

Journal of the American Academy of Dermatology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us